Posts made in February, 2012

According to the Medco Drug Trend report, by 2015 oncology drug costs will be the second or third costliest class that it tracks, up from seventh in 2011. That’s why, in this relatively unmanaged category,...

Payers, technology providers, and policy experts are convening in Las Vegas for the annual HIMSS fest to discuss how IT will enable new delivery models and payment reforms that are supposed to improve quality...

With falling prices and growing reimbursement hurdles, Europe is the last place most pharma want to be right now. One man’s hurdle is another’s opportunity, though. So it is for Medco, the US-based pharmacy...

As we told you in this recent post, a limited number of payers believe one way to better manage the current cancer drug spend is via cancer pathways, essentially a “soft formulary” approach that attempts to...

Every week Real Endpoints scours the web, the wires, and (sometimes) the weeds for the top reimbursement related news you need to know now. Below are our top picks for the past week. ExpressScripts/Medco: Who...

A little-reported fact about Germany’s new early-benefit assessment system (AMNOG to most people) is that the current law requires making public the rebates agreed to between drug firms and the country’s sick...

Payers like Aetna and UnitedHealth have a problem. Every year, they spend billions of dollars on their members’ cancer care, and those costs keep going up. And yet, they haven’t felt empowered to actually...